TB-500 Dosage and Protocol Guide: Injection, Timing, and Cycle (2026)

Executive Summary

TB-500 dosage and protocol are among the most common questions in the peptide recovery space — because TB-500 uses a distinctive two-phase dosing structure (loading then maintenance) that differs from most peptide protocols, and getting this structure right determines whether the protocol is effective. This guide covers the full dosing picture: standard loading and maintenance ranges, injection technique, timing, cycle structure, stacking with BPC-157, and what responsible clinical oversight looks like.

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring 43-amino acid peptide found in nearly every cell in the body. Its most studied effects involve systemic tissue repair — particularly accelerated healing of muscle, tendon, ligament, and connective tissue, along with anti-inflammatory effects and promotion of angiogenesis (new blood vessel growth). In US telehealth, it is available by prescription through compounding pharmacies and is primarily used for musculoskeletal recovery, chronic injury management, and as part of broader regenerative peptide stacks.

TB-500 is not FDA-approved for human use. It is available only through licensed US compounding pharmacies via physician prescription. The dosing parameters below reflect commonly prescribed telehealth protocols as of 2026 — they are not a substitute for individualized clinical guidance. Use this guide alongside our provider comparison tool, TB-500 overview, and BPC-157 and TB-500 stacking guide.

At-a-Glance Comparison

Standard TB-500 dosing parameters by phase as of 2026. Individual dosing should be determined by a licensed prescribing provider based on condition, weight, and response.

Understanding the Loading/Maintenance Structure: Why TB-500 Dosing Works Differently

TB-500's two-phase dosing structure is deliberate — not arbitrary. Understanding why it is structured this way helps you follow the protocol correctly and know when to adjust. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The loading phase serves to saturate tissue thymosin beta-4 levels above baseline. Because TB-500 acts on actin remodeling and cell migration pathways that govern tissue repair, the initial higher-dose phase is used to build tissue concentration and initiate the repair cascade. Think of it as priming the system. The maintenance phase sustains those elevated tissue levels at a lower dose once the initial saturation is achieved. This two-phase approach mirrors the pharmacology of several other regenerative compounds: high initial dose to establish therapeutic tissue levels, then lower dose to maintain. Loading phases typically run 4–6 weeks at 4–7.66 mg per week. Maintenance then drops to 2–2.5 mg per week for another 4–6 weeks. Total protocol: 8–12 weeks. Some providers use a simplified once-weekly dosing structure (e.g., 2.5 mg once per week throughout) for lower-intensity chronic injury management or general wellness protocols — this bypasses the loading phase but is less aggressive for acute repair needs. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Do not skip the loading phase for acute or significant injuries — the lower dose maintenance schedule used alone has less evidence for impact in the acute healing setting. If cost is a barrier, discuss dose adjustments with your provider rather than truncating the loading phase without guidance. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Step-by-Step Subcutaneous Injection Technique for TB-500

TB-500 is administered by subcutaneous injection in the same manner as other peptides. Here is the standard technique used by peptide clinic patients in 2026. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

1. Wash hands thoroughly with soap and water. 2. Wipe the rubber stopper of the vial with an alcohol swab; allow to air dry 10–15 seconds. 3. Draw air into the syringe equal to your intended dose volume. 4. Insert needle into the vial, inject air, then draw out your dose. 5. Remove needle; inspect for air bubbles — tap syringe and push bubbles out gently. 6. Clean the injection site with an alcohol swab; allow to dry. Best sites: abdomen (1–2 inches from navel), outer thigh, or lower back fat. 7. Pinch 1–2 inches of skin firmly. Insert the needle at a 45–90 degree angle. 8. Inject slowly and steadily — do not rush the injection. 9. Remove needle; apply light pressure with clean gauze or cotton. 10. Dispose of needle in an approved sharps container. Always rotate injection sites between doses. Standard 28–31G insulin syringes (0.5–1 mL) are used for subcutaneous peptide injections. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: TB-500 is occasionally associated with mild temporary fatigue or a transient flu-like feeling in the first 1–2 days after the first injection — particularly at loading doses. This typically resolves within 24 hours. Injection site reactions (redness, mild swelling) are normal. Persistent nodules, warmth, or increasing redness beyond 48 hours warrant provider contact. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Reconstituting TB-500: How to Mix the Powder Correctly

TB-500 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water. Getting reconstitution right ensures your dose math is accurate. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Common vial sizes are 2 mg and 5 mg. For a 2 mg vial: add 1 mL bacteriostatic water → concentration = 2,000 mcg/mL (2 mg/mL). For a 5 mg vial: add 2.5 mL bacteriostatic water → concentration = 2,000 mcg/mL. To add water: draw bacteriostatic water into a syringe, inject it slowly into the vial letting it run down the glass wall — do not spray directly onto the powder. Swirl gently until the powder fully dissolves. Do not shake — shaking can degrade peptide structure. The solution should be clear and colorless. Dose math example: for a 2 mg dose from a 2 mg/mL solution, draw 1 mL (100 units on a 100-unit insulin syringe). For a 2.5 mg dose, draw 1.25 mL — this requires two syringes or a larger syringe. For split-dose loading (e.g., 2.5 mg twice weekly), many providers use a 5 mg vial reconstituted with 2 mL (2,500 mcg/mL), making a 1 mg dose = 0.4 mL. Label your vial with the reconstitution date. Refrigerate and use within 30 days. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: TB-500 vials often contain more powder than labeled (overfill), but always dose to the labeled amount. If you see significant undissolved material after swirling, do not use — contact your pharmacy. Using non-bacteriostatic sterile water reduces stability to 24–48 hours post-reconstitution. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Dosage by Condition: What Protocols Look Like in Practice

TB-500 dosing is tailored to the severity and type of condition. Here are the commonly prescribed protocol structures for the most frequent use cases. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Acute musculoskeletal injury (ligament tear, tendon rupture, significant muscle strain): Loading 6–7.66 mg/week for 4–6 weeks (split 2–3 injections per week); maintenance 2.5 mg/week for 4–6 weeks. Full protocol: 10–12 weeks. Chronic musculoskeletal injury (recurring tendinopathy, partial tears, long-standing connective tissue issues): Loading 4–5 mg/week for 4 weeks; maintenance 2–2.5 mg/week for 6–8 weeks. Can be cycled 2–3 times per year. General recovery and performance maintenance: Simplified protocol — 2–2.5 mg once weekly throughout, no distinct loading phase. Often combined with BPC-157 or GH peptides. Anti-aging / connective tissue preservation: 2 mg bi-weekly (every two weeks) for ongoing maintenance between focused cycles. Minimal intervention approach for patients not dealing with acute injury. Stacked with BPC-157 (most common protocol for musculoskeletal repair): TB-500 loading 4–5 mg/week + BPC-157 250–500 mcg once daily simultaneously, for 6–8 weeks. Then maintain both at lower doses or cycle off TB-500 while continuing BPC-157 if gut/systemic repair is ongoing. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Higher loading doses (7+ mg/week) are associated with a higher rate of the transient fatigue/flu response in the first 1–2 doses. If this is a concern, some providers start at a lower loading dose (4 mg/week) and titrate up. Do not increase dose based on impatience — TB-500's tissue repair effects develop over weeks, not days. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Timing: When to Inject TB-500

Unlike GH secretagogues, TB-500 timing relative to meals and sleep is not critical. The main timing consideration is injection-day scheduling and site rotation. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

TB-500 can be injected at any time of day — fasted or fed. There is no GH pulse interaction to time around, and no evidence that food intake affects its tissue-level activity. Most patients inject in the morning or midday for practical reasons (easier to monitor for injection site reactions, and any transient fatigue is less disruptive during daytime). For twice-weekly injection schedules, the standard approach is to space injections roughly 3–4 days apart (e.g., Monday and Thursday) to maintain more consistent systemic levels throughout the week. For three-times-weekly loading doses, Monday/Wednesday/Friday is a common split. If stacking with BPC-157 (daily injections), many patients inject both peptides at the same time of day but at different sites. This is generally acceptable — the two peptides have no known pharmacokinetic interaction, and administering them in the same session simplifies adherence. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: If you experience transient fatigue after injection (especially at loading doses), consider shifting your injection day to a lower-demand day or injecting in the evening so it coincides with natural rest. This is a minor protocol adjustment, not a dose reduction. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Cycle Length, Breaks, and Long-Term Use

How long should a TB-500 protocol run, and when should you take a break? The answer differs between acute injury repair and ongoing musculoskeletal maintenance. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Standard full protocol: 8–12 weeks (4–6 week loading + 4–6 week maintenance). After a full cycle, take a 4–8 week break before repeating. This rest period prevents tissue desensitization and allows you to assess how much improvement carries forward after the cycle ends. For acute injuries, many patients require only one or two cycles. Once the injury resolves, no further TB-500 is warranted. For chronic conditions (e.g., recurring tendinopathy, degenerative joint changes), protocols may be cycled 2–3 times per year indefinitely, with provider monitoring. For ongoing performance or anti-aging use, a simplified bi-weekly low-dose protocol (2 mg every 2 weeks) allows periodic maintenance without full loading cycles. Annual labs (metabolic panel, CBC, and if applicable hormonal panels) are standard at responsible clinics running long-duration peptide protocols. TB-500 does not significantly affect HPTA, thyroid, or adrenal axes at standard doses — but a general health panel every 6–12 months is good practice for anyone running peptide protocols. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Continuous unmonitored use without breaks is not recommended given the absence of long-term human safety data. If your provider is renewing TB-500 prescriptions indefinitely without any reassessment or labs, that is a quality-of-care concern. Expect at minimum an annual check-in with updated history and labs. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Stacking TB-500 with BPC-157: The Most Effective Recovery Protocol

TB-500 and BPC-157 are the most commonly stacked peptides in musculoskeletal recovery — they have complementary and synergistic mechanisms. Here is how to run the stack correctly. Buyers searching for tb-500 dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

TB-500 primarily promotes systemic tissue repair through actin remodeling, cell migration, and angiogenesis — its effects are broad and systemic. BPC-157 promotes local healing through tendon fibroblast stimulation, nitric oxide signaling, and gut-protective pathways — it is more targeted and direct. Together, they address both systemic repair signaling (TB-500) and local tissue reconstruction (BPC-157). Standard combined protocol: TB-500 loading 4–5 mg/week × 4–6 weeks + BPC-157 250–500 mcg SC once daily. After the loading phase, TB-500 drops to maintenance (2–2.5 mg/week) while BPC-157 may continue at the same daily dose or taper. Total combined protocol: 8–12 weeks. Inject them at separate sites — different areas of the abdomen, or one in the abdomen and one in the outer thigh. You do not need to separate them in time — the same injection session is fine. Both are stored separately and administered from separate syringes. Do not mix in the same syringe. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Running both at full doses simultaneously increases total peptide load. If you experience unexpected side effects (unusual fatigue, rapid changes in any health markers), it is harder to attribute the cause when running two peptides simultaneously. Some providers prefer staggering the start — beginning BPC-157 first for 2 weeks, then adding TB-500 loading — so any early reactions can be attributed to a single compound. Discuss this approach with your provider if you prefer a cleaner tolerability picture. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If you are evaluating TB-500 for injury recovery, chronic musculoskeletal repair, or as part of a broader peptide protocol, the right starting point is a licensed provider consultation with baseline labs. Our provider comparison tool helps you find telehealth clinics that prescribe TB-500 responsibly — with verified US compounding pharmacies, written protocols, and follow-up monitoring. Our best peptide clinics 2026 guide is also a strong starting point.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is the standard TB-500 dosage?

The most commonly prescribed loading dose is 4–7.66 mg per week, split over 2–3 subcutaneous injections. Maintenance doses are 2–2.5 mg per week after the loading phase. For general wellness or performance maintenance without an acute injury, some providers use a simplified 2–2.5 mg once-weekly protocol without a distinct loading phase.

How do I inject TB-500 subcutaneously?

Use a 28–31G insulin syringe. Wipe the vial stopper and injection site with alcohol. Draw your dose. Pinch skin at the injection site (abdomen, outer thigh, or lower back fat). Insert at a 45–90 degree angle. Inject slowly. Remove the needle and apply light pressure. Rotate injection sites at every dose. Dispose of needles in a sharps container.

How do I reconstitute TB-500?

Add bacteriostatic water slowly into the lyophilized vial — aim for a 2 mg/mL concentration (e.g., 1 mL water into a 2 mg vial; 2.5 mL into a 5 mg vial). Swirl gently until dissolved. Do not shake. Label with reconstitution date and refrigerate. Use within 30 days.

What is a TB-500 loading dose?

A loading dose is a higher-than-maintenance dose used at the start of the protocol to rapidly build therapeutic tissue levels of thymosin beta-4. Loading doses are typically 4–7.66 mg per week split over 2–3 injections, for 4–6 weeks. After loading, dosing drops to 2–2.5 mg per week for the maintenance phase.

How long does a TB-500 cycle last?

A full protocol typically runs 8–12 weeks — 4–6 weeks loading plus 4–6 weeks maintenance. After the cycle, take a 4–8 week break before assessing whether another cycle is needed. Acute injuries often resolve in one or two cycles. Chronic conditions may warrant 2–3 cycles per year.

Can I stack TB-500 with BPC-157?

Yes — TB-500 and BPC-157 are the most commonly combined peptides for musculoskeletal repair. They have complementary mechanisms: TB-500 promotes systemic tissue repair through actin remodeling and angiogenesis; BPC-157 drives local tendon/tissue reconstruction through fibroblast stimulation and nitric oxide pathways. Standard stack: TB-500 at loading/maintenance doses + BPC-157 250–500 mcg once daily. Use separate syringes and injection sites.

When should I inject TB-500 — morning or evening?

TB-500 timing relative to meals or time of day is not critical — it does not interact with GH pulses or insulin sensitivity the way GH secretagogues do. Most patients inject in the morning for consistency. If you experience transient fatigue after the first few loading doses, shifting to an evening injection may be more comfortable.

What side effects should I watch for?

TB-500 has a generally favorable tolerability profile at standard doses. The most common side effect is mild, transient fatigue or a brief flu-like feeling in the 12–24 hours following the first few loading-phase injections — this typically resolves quickly. Injection site reactions (redness, mild swelling) are normal. TB-500 does not significantly suppress the HPTA or affect cortisol/thyroid at standard doses. Contact your provider if you experience unusual or persistent symptoms.

Does TB-500 require a prescription?

Yes — TB-500 (thymosin beta-4 analog) requires a prescription from a licensed physician and is dispensed by US compounding pharmacies. It is not FDA-approved and not legally available for human use through research chemical suppliers. Look for providers that require labs, provide written protocols, and use verified US compounding pharmacies.

Where can I get TB-500 prescribed?

TB-500 is prescribed by some telehealth men's health and peptide clinics that specialize in regenerative medicine. Look for providers requiring baseline labs, written dosing protocols, and follow-up monitoring. Our provider comparison tool and best peptide clinics guide are the best places to start.